Skip to main content Back to Top
Advertisement

7/30/2022

Fosphenytoin Sodium Injection

Products Affected - Description

    • Cerebyx solution for injection, Pfizer, 50 mg phenytoin equivalents/mL, 2 mL single dose vial, 25 count, NDC 00069-6001-25
    • Fosphenytoin sodium solution for injection, Fresenius Kabi, 50 mg phenytoin equivalents/mL, 10 mL single dose vial, 10 count, NDC 63323-0403-10
    • Fosphenytoin sodium solution for injection, Fresenius Kabi, 50 mg phenytoin equivalents/mL, 2 mL single dose vial, 25 count, NDC 63323-0403-02
    • Fosphenytoin sodium solution for injection, Hikma, 50 mg phenytoin equivalents/mL, 10 mL single dose vial, 10 count, NDC 00641-6137-10
    • Fosphenytoin sodium solution for injection, Hikma, 50 mg phenytoin equivalents/mL, 2 mL single dose vial, 25 count, NDC 00641-6136-25

Reason for the Shortage

    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Pfizer has Cerebyx on shortage due to increased demand.

Available Products

    • Cerebyx solution for injection, Pfizer, 50 mg phenytoin equivalents/mL, 10 mL single dose vial, 10 count, NDC 00069-6001-21

Estimated Resupply Dates

    • Fresenius Kabi has fosphenytoin sodium 2 mL and 10 mL vials on back order and the company cannot estimate a release date.
    • Hikma has fosphenytoin 2 mL vials on back order and the company estimates a release date of 1st quarter 2023. The 10 mL vials are on back order and the company cannot estimate a release date.
    • Pfizer has Cerebyx 2 mL vials on back order and the company estimates a release date in August 2022.

Updated

Updated July 30, 2022 by Elyse MacDonald, PharmD, MS, BCPS. Created April 14, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.